{
    "title": "Actelion drug setback unlikely to derail J&J talks - analysts",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4147058/Actelions-Opsumit-drug-missed-trial-endpoint--doctor.html",
    "date": "2017-01-23",
    "keywords": [
        "opsumit",
        "drug",
        "actelion",
        "gmt",
        "test",
        "hypertension",
        "tracleer",
        "impact",
        "deal",
        "johnson",
        "part",
        "endpoint",
        "exercise",
        "capacity",
        "walk",
        "pah",
        "treatment",
        "setback",
        "jj",
        "email",
        "john",
        "millerzurich",
        "blow",
        "monday",
        "percent",
        "company",
        "target",
        "latestage",
        "study",
        "heartlung",
        "ailmentactelion",
        "phase",
        "trial",
        "push",
        "use",
        "eisenmenger",
        "syndrome",
        "heart",
        "lead",
        "blood",
        "lung",
        "narrowopsumit",
        "medicine",
        "patent",
        "sixminute",
        "revenue",
        "potential",
        "year",
        "jjs",
        "interest",
        "biotech",
        "groupthe",
        "failure",
        "disappointment",
        "companys",
        "price",
        "pressure",
        "deutsche",
        "bank",
        "analyst",
        "richard",
        "quarter",
        "minor",
        "europe",
        "benefit",
        "effect",
        "minute",
        "head",
        "center",
        "university",
        "institute",
        "result",
        "improvement",
        "studys",
        "placebo",
        "arm",
        "phenomenon",
        "michael",
        "alexander",
        "smith"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}